Table 1

IC50 values determined by nonlinear regression of MTT assay data (see Figure 4)

697 Human B-ALL cell lines
Wild-typeshControlshMer1AshMer1B
6-MP, μmol/L     
    IC50 64 > 64 2.86 3.24 
    99% CI ND ND 2.2-3.7 2.5-4.2 
    P < .01 ND  ND ND 
MTX, nmol/L     
    IC50 27.5 27.8 12.3 11.8 
    99% CI 23.8-31.7 24.4-31.6 10.3-14.7 10.6-13.1 
    P < .01 NS  * * 
VCR, nmol/L     
    IC50 1.04 1.02 0.54 0.46 
    99% CI 0.84-1.29 0.84-1.23 0.46-0.63 0.37-0.55 
    P < .01 NS  * * 
VP-16, nmol/L     
    IC50 181 173 54.0 60.3 
    99% CI 124-264 124-242 43.5-66.8 49.8-73.0 
    P < .01 NS  * * 
DOXO, nmol/L     
    IC50 16.7 11.1 2.83 3.26 
    99% CI 12.4-22.4 7.17-17.2 2.20-3.64 2.44-4.35 
    P < .01 NS  * * 
697 Human B-ALL cell lines
Wild-typeshControlshMer1AshMer1B
6-MP, μmol/L     
    IC50 64 > 64 2.86 3.24 
    99% CI ND ND 2.2-3.7 2.5-4.2 
    P < .01 ND  ND ND 
MTX, nmol/L     
    IC50 27.5 27.8 12.3 11.8 
    99% CI 23.8-31.7 24.4-31.6 10.3-14.7 10.6-13.1 
    P < .01 NS  * * 
VCR, nmol/L     
    IC50 1.04 1.02 0.54 0.46 
    99% CI 0.84-1.29 0.84-1.23 0.46-0.63 0.37-0.55 
    P < .01 NS  * * 
VP-16, nmol/L     
    IC50 181 173 54.0 60.3 
    99% CI 124-264 124-242 43.5-66.8 49.8-73.0 
    P < .01 NS  * * 
DOXO, nmol/L     
    IC50 16.7 11.1 2.83 3.26 
    99% CI 12.4-22.4 7.17-17.2 2.20-3.64 2.44-4.35 
    P < .01 NS  * * 

Cumulative data from at least 3 independent experiments performed in triplicate were analyzed.

CI indicates confidence interval; DOXO, doxorubicin; 6-MP, 6-mercaptopurine; MTX, methotrexate; ND, not determined; NS, not significant; VCR, vincristine; and VP-16, etoposide.

*

Significance vs shControl is indicated by nonoverlapping 99% CIs. Significance could not be statistically evaluated for 6-MP–treated cells because an IC50 was not reached for wild-type or shControl cells.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal